Mimedx Group, INC Form 4 insider transactions

MiMedx Group, Inc. announced an Agreement and Plan of Merger to acquire Sanara MedTech Inc. for a combination of cash and stock, aiming to enhance its market position.

MiMedx Group Inc. announced its definitive agreement to acquire Sanara MedTech Inc. for $35 per share, a move expected to significantly expand its surgical business and create a leading regenerative medicine company.

MIMEDX and Sanara MedTech announced a definitive agreement for MIMEDX to acquire Sanara, aiming to create a larger regenerative medicine company in the surgical space.

MiMedx announced an agreement to acquire Sanara MedTech, aiming to bolster its regenerative medicine offerings and expand its surgical business.

MiMedx Group, Inc. reported a 35% decrease in Q2 2026 net sales to $64 million, driven by a 61% drop in Wound sales due to Medicare reimbursement changes, while Surgical sales grew 15%. The company also announced the acquisition of Sanara MedTech for approximately $350 million.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million.

Mimedx Group, Inc. Chief Financial Officer Doug Rice reported a transaction involving the withholding of shares for tax payments related to restricted stock units.

MIMEDX Group, Inc. Chief Commercial Officer Kimberly Maersk-Moller reported a transaction involving the sale of 19,820 shares to cover tax withholding obligations.

Director James L. Bierman acquired 50,913 shares of MiMedx Group, Inc. common stock as part of an annual restricted stock grant.

Director Dorothy Puhy acquired 50,913 shares of MiMedx Group common stock as part of an annual restricted stock grant.

Director Todd Newton acquired 50,913 shares of MiMedx Group, Inc. common stock as part of an annual restricted stock grant.

Director William A. Hawkins acquired 50,913 shares of MiMedx Group, Inc. common stock as part of an annual restricted stock grant.

Director Tiffany Olson received an annual restricted stock grant of 50,913 shares of MiMedx Group, Inc. common stock.

MIMEDX Group's General Counsel, William Frank Hulse IV, reported a disposition of 20,245 shares of common stock for tax withholding related to restricted stock vesting.

MIMEDX Group's Chief Commercial Officer, Kimberly Maersk-Moller, reported a routine disposition of shares for tax withholding purposes.

MIMEDX Group's Chief Commercial Officer, Kimberly Maersk-Moller, acquired 42,845 shares of common stock through PSU vesting and simultaneously disposed of 21,270 shares for tax obligations.

MIMEDX General Counsel William Hulse IV increased his direct beneficial ownership by 74,904 shares after vesting of performance stock units and tax-related sales.

MIMEDX Group's Chief Financial Officer, Doug Rice, increased his direct ownership by 146,637 shares following the vesting of performance stock units.

MIMEDX GROUP, INC. CEO Joseph Capper received substantial grants of restricted stock and stock options, aligning his incentives with long-term company performance.

MiMedx Group's CFO, Doug Rice, received significant equity grants including restricted stock and stock options, aligning his incentives with long-term company performance.

MIMEDX GROUP's General Counsel and CAO, William Frank Hulse IV, was granted 74,987 restricted stock units and 62,758 stock options.

MIMEDX Group's Chief Operating Officer, Ricci S. Whitlow, received a grant of restricted stock and stock options as part of compensation.

MIMEDX Group's Chief Commercial Officer, Kimberly Maersk-Moller, was granted 74,163 restricted shares and 62,068 stock options.

Kimberly Maersk-Moller, Chief Commercial Officer of MiMedx Group, Inc., sold 58,300 shares of common stock for approximately $432,000 under a pre-arranged trading plan.

MIMEDX Group's Chief Financial Officer, Doug Rice, reported the disposition of 12,749 shares of common stock at $6.34 per share to cover tax liabilities related to restricted stock unit vesting.

MIMEDX Group's Chief Commercial Officer, Kimberly Maersk-Moller, reported the disposition of 12,034 shares of common stock at $5.96 per share, primarily for tax liability upon restricted stock unit vesting.

MIMEDX Group, Inc. Director Todd Newton was granted 28,609 shares of common stock as part of his annual restricted stock compensation, valued at $6.47 per share.

M. Kathleen Behrens, a Director at MIMEDX GROUP, INC., acquired 28,609 shares of common stock valued at $6.47 per share as part of her annual restricted stock grant.

MIMEDX Group, Inc. Director James L. Bierman was granted 28,609 shares of common stock as part of his annual restricted stock compensation.

MIMEDX Group, Inc. Director William A. Hawkins reported the acquisition of 28,609 shares of common stock as part of an annual restricted stock grant, increasing his total beneficial ownership to 204,018 shares.